Research suggests that combining adagrasib with cetuximab may be a potential standard treatment for colorectal cancer with a KRAS G12C mutation. This combination has shown efficacy in treating the disease, with studies indicating it is well-tolerated and has antitumor effects. Other treatments, including encorafenib and divarasib, are also being explored for their potential in treating colorectal cancer with specific mutations.